CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Recruiting
N/A
Interventional Study
Solid Tumor
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 15 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1\. Aged \>18 years old; ECOG 0 or 1;
* 2\. Patients with solid tumors;
* 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
* 4\. life expectancy \>=12 weeks.
Exclusion Criteria:
* 1\. Significant hepatic o…
Contacts